GMAB Berita Valas

$Genmab Submits NDA For Epcoritamab In Japan For Relapsed/Refractory Large B-Cell Lymphoma$

Genmab Submits NDA For Epcoritamab In Japan For Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S (GMAB) announced Wednesday that the company has submitted a Japan new drug application (JNDA) to the Ministry of Health, Labor and Welfare (MHLW) of Japan for subcutaneous epcoritamab (DuoBody-CD3xCD20)

RTTNews | 1014 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.1734	GBPUSD	1.3442	AUDUSD	0.661
USDJPY	147.847	USDCAD	1.39184	USDCHF	0.79567